Amphastar Pharmaceuticals completed the acquisition of BAQSIMI from Eli Lilly for $1.1bn.

Amphastar Pharmaceuticals, a specialty pharmaceutical company, completed the acquisition of BAQSIMI, a diabetes medication from Eli Lilly, a pharmaceutical company, for $1.1bn. "We are pleased to execute our strategy to accelerate the expansion of our branded products and diabetes portfolio, as evidenced by the successful completion of the acquisition of BAQSIMI. We have further strengthened our commercial product portfolio by adding BAQSIMI while remaining committed to our core business. We are committed to maximizing the commercial potential of BAQSIMI while assisting people with diabetes worldwide," Jack Zhang, Amphastar President and CEO.